Clin2
NCT07785934Possibly a fitRecruiting

Testing a new weight management injection for drug interactions

Drug Drug Interaction (DDI)Pharmacokinetics and Pharmacodynamics

Treatments studied

Part of Hormones & metabolism clinical trials.

This study tests a new injectable medication for weight management in people with overweight or obesity. It investigates how the drug interacts with other medications and checks its safety. Participation requires a 6-month commitment with regular study visits.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1
Enrollment
48 people
Ages
18 years to 45 years
Study type
Interventional

Who can take part

  • Between 18 and 45 years old
  • BMI between 24 and 35
  • Body weight at least 50 kg
  • Willing to use contraception and avoid conception for 6 months after the study
  • No significant medical conditions or allergies to similar drugs
  • No use of certain medications or supplements within 2 weeks before the study
  • No recent vaccination or participation in another clinical trial within 3 months

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07630233Not yet recruiting· Phase 1
Safety and effects of UBT38006 injection in healthy men

This early-stage study tests a new injectable medication (UBT38006) in healthy adult men to understand how safe it is and how the body processes it. Researchers want to make sure the injection doesn't cause serious side effects and works as expected.

Hefei, Anhui
NCT07224399Recruiting· Phase 1
Testing a new injection for weight loss in obesity

This trial tests a new injection (BGM1812) for weight loss in people who are overweight or obese. The injection is given under the skin, and the study will see how it works in your body and how safe it is.

Baltimore, Maryland
NCT06670209Not yet recruiting· Phase 1
Drug interaction study for weight management medication

This study tests how a new injectable weight loss drug affects the way the body processes metformin, a common diabetes medication. It is for Chinese adults who are overweight or obese.

NCT07382908Recruiting· Phase 1
Bioequivalence study of an injection for weight management

This trial tests if a new injection works the same as the approved version in overweight or obese adults. It may help if you are looking for a weight management treatment.

Hangzhou, Zhejiang
NCT07532655Not yet recruiting· Phase 1
Testing a New Weight-Loss Injection in Healthy Adults

This study tests a new injectable medication (SYH2082) that works like GLP-1 and GIP drugs to see how safe it is and how your body handles it. You must be healthy with no diabetes, thyroid cancer risk, or recent major surgery.

NCT07659574Not yet recruiting· Phase 3
Study of UBT251 injection for type 2 diabetes not controlled by diet and exercise

This trial tests a new injected drug (UBT251) for people with type 2 diabetes who haven't been able to control their blood sugar with diet and exercise alone. It aims to see if the drug can help lower blood sugar levels safely.

Hunan, Changsha

Hear when a new Pharmacokinetics and Pharmacodynamics trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.